A detailed history of Grimes & Company, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 100,241 shares of ABBV stock, worth $16.4 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
100,241
Previous 99,361 0.89%
Holding current value
$16.4 Million
Previous $15.4 Million 18.55%
% of portfolio
0.57%
Previous 0.51%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$159.82 - $182.1 $140,641 - $160,248
880 Added 0.89%
100,241 $18.3 Million
Q4 2023

Jan 24, 2024

BUY
$137.6 - $154.97 $584,937 - $658,777
4,251 Added 4.47%
99,361 $15.4 Million
Q3 2023

Oct 19, 2023

SELL
$133.59 - $154.65 $24,714 - $28,610
-185 Reduced 0.19%
95,110 $14.2 Million
Q2 2023

Jul 19, 2023

BUY
$132.51 - $164.9 $91,166 - $113,451
688 Added 0.73%
95,295 $12.8 Million
Q1 2023

Apr 20, 2023

BUY
$144.61 - $166.54 $466,078 - $536,758
3,223 Added 3.53%
94,607 $15.1 Million
Q4 2022

Jan 25, 2023

BUY
$138.31 - $165.87 $428,207 - $513,533
3,096 Added 3.51%
91,384 $0
Q3 2022

Oct 28, 2022

BUY
$134.21 - $153.93 $113,675 - $130,378
847 Added 0.97%
88,288 $11.8 Million
Q2 2022

Jul 22, 2022

SELL
$137.62 - $174.96 $56,286 - $71,558
-409 Reduced 0.47%
87,441 $13.4 Million
Q1 2022

May 06, 2022

BUY
$131.98 - $163.75 $103,604 - $128,543
785 Added 0.9%
87,850 $14.2 Million
Q4 2021

Feb 01, 2022

BUY
$107.43 - $135.93 $87,125 - $110,239
811 Added 0.94%
87,065 $11.8 Million
Q3 2021

Nov 08, 2021

BUY
$106.4 - $120.78 $158,216 - $179,599
1,487 Added 1.75%
86,254 $9.3 Million
Q2 2021

Aug 04, 2021

BUY
$105.21 - $117.21 $182,644 - $203,476
1,736 Added 2.09%
84,767 $9.55 Million
Q1 2021

May 12, 2021

BUY
$102.3 - $112.62 $683,466 - $752,414
6,681 Added 8.75%
83,031 $8.99 Million
Q4 2020

Feb 02, 2021

BUY
$80.49 - $108.67 $141,742 - $191,367
1,761 Added 2.36%
76,350 $8.18 Million
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $76,202 - $89,436
887 Added 1.2%
74,589 $6.53 Million
Q2 2020

Jul 31, 2020

BUY
$73.37 - $98.18 $48,130 - $64,406
656 Added 0.9%
73,702 $7.24 Million
Q1 2020

May 05, 2020

BUY
$64.5 - $97.79 $1.77 Million - $2.68 Million
27,396 Added 60.01%
73,046 $5.57 Million
Q4 2019

Feb 05, 2020

BUY
$72.13 - $90.25 $35,704 - $44,673
495 Added 1.1%
45,650 $4.04 Million
Q3 2019

Nov 05, 2019

BUY
$62.98 - $75.72 $52,462 - $63,074
833 Added 1.88%
45,155 $3.42 Million
Q2 2019

Jul 30, 2019

BUY
$65.7 - $83.98 $7,029 - $8,985
107 Added 0.24%
44,322 $3.22 Million
Q1 2019

May 02, 2019

SELL
$77.14 - $90.79 $4,474 - $5,265
-58 Reduced 0.13%
44,215 $3.56 Million
Q4 2018

Feb 01, 2019

SELL
$77.85 - $96.01 $78,472 - $96,778
-1,008 Reduced 2.23%
44,273 $4.08 Million
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $1,422 - $1,581
-16 Reduced 0.04%
45,281 $4.28 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $10,055 - $11,897
-112 Reduced 0.25%
45,297 $4.2 Million
Q1 2018

May 07, 2018

BUY
$92.01 - $123.21 $1.25 Million - $1.67 Million
13,546 Added 42.51%
45,409 $4.3 Million
Q4 2017

Feb 05, 2018

BUY
$89.56 - $98.21 $2.47 Million - $2.71 Million
27,567 Added 641.69%
31,863 $3.08 Million
Q3 2017

Nov 03, 2017

BUY
$69.85 - $89.22 $300,075 - $383,289
4,296
4,296 $382,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $290B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.